Evexia Lifecare Ltd. (BSE: 524444), engaged in the trading of chemicals, manufacturing of intermediates, agricultural produce and various other products of consumer goods, has announced that the members of the company approved the issue of the foreign currency
convertible bonds in the Annual General Meeting held on July 9, 2022. The board has considered and approved conversion of 25 bonds into equity shares as per the terms and conditions of the issue of FCCB. Recently, the Board of Directors at its meeting held on June 17, 2024 had also considered and approved conversion of 75 bonds into equity shares as per the terms and conditions of the issue of FCCB.
Earlier, Evexia Lifecare Ltd. Announced that it had incorporated a Subsidiary Company namely “EVEXIA LIFECARE AFRICA LIMITED (CIN: 14497377)” which is registered with the Registrar of Companies for England and Wales. The Registrar of Companies for England and Wales has issued a Certificate of Incorporation for the same. Evexia Lifecare Formed the New Subsidiary to Set Up Pathology Labs in Africa.
Evexia Lifecare Ltd. (BSE: 524444) is engaged in the trading of pharmaceuticals, chemicals, manufacturing of intermediates, agricultural produce and various other products of consumer goods. It is mainly engaged in the trading of pharma chemicals. The Company in trading of various petrochemical downstream products, such as special oils, special chemicals, petroleum sulphates and solvents for industrial applications, such as rubber,
leather, ink and paint industries. Its products include pharma intermediates, plastic granule, chemicals, and gold and diamond. The Company focuses to expand its line of business in Web development, software development for overseas clients, trading in gold and entertainment segment.